Monumental-6: A Phase 3 Study of Talquetamab plus Pomalidomide or Talquetamab plus Teclistamab Vs Elotuzumab plus Pomalidomide plus Dexamethasone (EPd) or Pomalidomide plus Bortezomib plus Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

被引：0
|
作者：
Nooka, Ajay K.
Mian, Hira [1 ]
Lee, Cindy [2 ]
Rodriguez-Otero, Paula [3 ]
Kumar, Shaji [4 ]
Einsele, Hermann [5 ]
Vishwamitra, Deeksha [6 ]
Vieyra, Diego [6 ]
Kane, Colleen [6 ]
Kosh, Michele [6 ]
Masterson, Tara J. [6 ]
Heuck, Christoph [7 ]
Kansagra, Ankit [7 ]
Moreau, Philippe [8 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[2] McMaster Univ, Hamilton, ON, Canada
[3] Royal Adelaide Hosp, Adelaide, Australia
[4] Clin Univ Navarra, Madrid, Spain
[5] Mayo Clin, Div Hematopathol, Rochester, MN USA
[6] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[7] Janssen Res & Dev, Spring House, PA USA
[8] Univ Hosp, Nantes, France
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-199752
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：47571 / 47572
页数：2
相关论文
共 50 条
  • [41] Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status
    Decaux, Olivier
    Lafore, Radhia
    Iaquinta, Daniel
    Tekle, Christina
    Leleu, Xavier
    BLOOD, 2022, 140 : 10969 - 10970
  • [42] Daratumumab in combination with bortezomib plus dexamethasone or lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma: phase 3 CASTOR and POLLUX subgroup analyses in patients with early or late relapse after initial therapy
    Goldschmidt, H.
    Spencer, A.
    Moreau, P.
    Mateos, M. V.
    Suzuki, K.
    Levin, M. D.
    Sonneveld, P.
    Yoon, S. S.
    Usmani, S. Z.
    Weisel, K.
    Reece, D.
    Ahmadi, T.
    Pei, H.
    Mayo, W. G.
    Gai, X.
    Carey, J.
    Carson, R.
    Dimopoulos, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 142 - 142
  • [43] ADVERSE EVENTS AND MANAGEMENT IN MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Delforge, M.
    Dimopoulos, M.
    Weisel, K.
    Moreau, P.
    Lacy, M.
    Song, K.
    Karlin, L.
    Goldschmidt, H.
    Banos, A.
    Oriol, A.
    Alegre, A.
    Chen, C.
    Cavo, M.
    Garderet, L.
    Ivanova, V.
    Martinez-Lopez, J.
    Yu, X.
    Sternas, L.
    Jacques, C.
    Zaki, M.
    Miguel, J.
    HAEMATOLOGICA, 2013, 98 : 329 - 330
  • [44] MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: OUTCOMES BY PRIOR THERAPY AND RESPONSE DEPTH
    San Miguel, J. F.
    Weisel, K. C.
    Song, K. W.
    Delforge, M.
    Karlin, L.
    Goldschmidt, H.
    Moreau, P.
    Banos, A.
    Oriol, A.
    Garderet, L.
    Cavo, M.
    Ivanova, V.
    Alegre, A.
    Martinez-Lopez, J.
    Chen, C. I.
    Renner, C.
    Bahlis, N. Jacques
    Yu, X.
    Teasdale, T.
    Sternas, L.
    Jacques, C.
    Zaki, M. H.
    Dimopoulos, M. A.
    HAEMATOLOGICA, 2014, 99 : 110 - 110
  • [45] Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM): efficacy results after additional follow-up of the phase 2, randomized ELOQUENT-3 study
    Raab, M. S.
    Dimopoulos, M. A.
    Dytfeld, D.
    Grosicki, S.
    Moreau, P.
    Takezako, N.
    Hori, M.
    Leleu, X.
    LeBlanc, R.
    Suzuki, K.
    Richardson, P. G.
    McKiver, Popa M.
    Jou, Y. -M.
    Shelat, S. G.
    Robbins, M.
    Rafferty, B.
    San-Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 192 - 193
  • [46] The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in refractory or relapsed and refractory multiple myeloma
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    Cavo, Michele
    Corradini, Paolo
    Delforge, Michel
    Morgan, Gareth J.
    Hansson, Markus
    Palumbo, Antonlo
    Oclo, Enrique M.
    Simcock, Mathew
    Miller, Neil
    Slaughter, Ana
    Leupin, Nicolas
    Nikolova, Zariana G.
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Perez, Raymond
    Baz, Rachid
    Richardson, Paul G.
    Anderson, Kenneth C.
    Sabbatini, Peter
    Dilea, Clifford
    Cardarelli, Pina M.
    Wade, Mark
    Xing, Guan
    Gutierrez, Andres
    Cohen, Lewis
    Becker, Pamela S.
    BLOOD, 2014, 124 (21)
  • [48] Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials
    Dechow, Tobias
    Aldaoud, Ali
    Behlendorf, Timo
    Knauf, Wolfgang
    Eschenburg, Henning
    Groschek, Matthias
    Hansen, Richard
    Soeling, Ulrike
    Grebhardt, Sina
    Siebenbach, Hans Ulrich
    Vannier, Corinne
    Potthoff, Karin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 108 (02) : 133 - 144
  • [49] MM-013 PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT
    Sonneveld, P.
    Weisel, K.
    van de Donk, N.
    Ramasamy, K.
    Gamberi, B.
    Streetly, M.
    Offidani, M.
    Bridoux, F.
    de la Rubia, J.
    Kueenburg, E.
    Collins, S.
    Di Micco, A.
    Rosettani, B.
    Bacon, P.
    Dimopoulos, M.
    HAEMATOLOGICA, 2017, 102 : 113 - 114
  • [50] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Malinge, Laure
    Dubin, Franck
    van de Velde, Helgi
    Anderson, Kenneth C.
    LANCET ONCOLOGY, 2022, 23 (03): : 416 - 427
12345